Raras
Buscar doenças, sintomas, genes...
Primary vitreoretinal large B-cell lymphoma
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Linfoma intraocular é uma forma maligna rara de câncer ocular. O linfoma intraocular pode afetar o olho secundariamente a partir de uma metástase de um tumor não-ocular ou pode surgir primariamente dentro do olho. O LIO P é um subtipo de linfoma primário do sistema nervoso central (LPSNC). Os LPSNC são mais comumente um subtipo imunohistoquímico de linfoma difuso de grandes células B não-Hodgkin, de acordo com a classificação de linfomas da Organização Mundial da Saúde (OMS). Os sintomas mais comuns do LIO P incluem visão turva ou diminuída devido a células tumorais no vítreo. A maioria dos casos de LIO P evoluem para envolvimento do sistema nervoso central (LPSNC), enquanto apenas 20% dos LPSNC levam a envolvimento intraocular (LIO P).

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos95publicações
Pico202515 papers
Linha do tempo
20202015Hoje · 2026🧪 2013Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
1Fase 12
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Primary vitreoretinal large B-cell lymphoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
0 papers (10 anos)
#1

Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.

Scientific reports2026 Feb 14

Vitreoretinal large B-cell lymphoma (VR-LBCL) is a rare hematologic malignancy. It is classified as primary (PVR-LBCL) or secondary (SVR-LBCL) based on the initial site of manifestation. Owing to limited prospective data and absent standardized guidelines, treatment remains challenging. This dual-center retrospective study aimed to evaluate outcomes of methotrexate (MTX) intravitreal (itv.), Rituximab itv., or combinatorial itv. therapy (R-MTX) and assess the impact of additional systemic immunochemotherapy. Among 65 patients (median age 72 years) included, 55.4% (n = 36) had PVR-LBCL. The median time to diagnosis was 31 days (1–2805). Over a median follow-up of 23.2 months, 35 patients relapsed. MTX itv. showed a trend toward better ocular relapse-free-survival than Rituximab itv. (P = 0.07). Intriguingly, patients receiving R-MTX itv. experienced no relapses throughout follow-up. In general, addition of systemic therapy was associated with significantly longer relapse-free-survival compared to itv. monotherapy (P = 0.05). Keratopathy and elevated intraocular pressure were common side effects with MTX itv. and Rituximab itv., respectively. Despite compelling findings and being one of the largest cohorts published to date, the heterogeneity of the patient population and small subgroups limit direct clinical translation. Nonetheless, this study provides a strong foundation for the design of future clinical trials. The online version contains supplementary material available at 10.1038/s41598-026-37804-4.

#2

Immune-Mediated Macular Edema After Intravitreal Methotrexate in Primary Vitreoretinal Lymphoma.

Ocular immunology and inflammation2026 Feb

To report a case of cystoid macular edema in a patient with primary vitreoretinal lymphoma (PVRL) following intravitreal methotrexate (MTX) and lymphoma remission. Case report. A 76-year-old man was diagnosed with PVRL after a 9-month history of bilateral floaters and progressive blurred vision. Vitreous biopsy revealed CD20-positive large B cells, a MYD88 (L265P) mutation, and interleukin IL-10/IL-6 ratio of 1.76 at diagnosis. Systemic involvement was initially excluded but metachronous brain lesions emerged, prompting systemic chemotherapy.Macular edema developed after 2 and 6 weeks of MTX in the left and right eyes, respectively, coinciding with inversion of the IL-10/IL-6 ratio to 0.01. Edema was refractory to topical therapy and required intravitreal dexamethasone and aflibercept. The simultaneous inversion of the IL-10/IL-6 ratio with edema onset suggests a cytokine shift unmasking an inflammatory response previously suppressed by malignant lymphoproliferation. This pattern supports an immune reconstitution inflammatory syndrome-like mechanism as the most likely cause.

#3

Intraocular Lymphoma: A Review.

Journal of ophthalmic & vision research2025

Intraocular lymphoma (IOL) is a rare form of non-Hodgkin lymphoma that primarily presents in two distinct types. The first type, known as primary intraocular lymphoma (PIOL), is mainly recognized as a subtype of primary central nervous system lymphoma (PCNSL). Recent classifications have emphasized the primary ocular sites affected, with vitreoretinal lymphoma emerging as the most common variant linked to PCNSL. Despite its rarity, the incidence of PIOL is rising among both immunocompromised and immunocompetent populations. Most cases of PIOL are identified as diffuse large B-cell lymphoma, although rare T-cell variants have also been reported. Secondary intraocular lymphoma (SIOL) originates from metastatic spread of non-CNS lymphomas to the ocular structures, including the retina, uvea, vitreous body, Bruch's membrane, and optic nerve. Diagnosis of IOL is challenging for ophthalmologists and pathologists, as it can easily mimic other ocular conditions. Advancements in laboratory diagnostics, such as immunocytochemistry, flow cytometry, and the evaluation of interleukin ratios (specifically IL-10:IL-6 > 1), along with polymerase chain reaction (PCR) amplification for clonality, have enhanced diagnostic accuracy. Multimodal imaging approaches and molecular analyses can serve as valuable indicators of visual prognosis, recurrence rates, and the likelihood of progression to central nervous system involvement. Given that misdiagnosis or delayed diagnosis can result in serious treatment delays and potentially life-threatening outcomes for patients with IOL, this review seeks to provide a comprehensive understanding of the clinical manifestations of IOL and the diagnostic methods employed.

#4

Clinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.

Cancer research and treatment2025 Aug 13

Immune-privileged large B-cell lymphomas (IP-LBCLs), comprising primary central nervous system lymphoma (PCNS-LBCL), primary vitreoretinal lymphoma (PVR-LBCL), and primary testicular lymphoma (PT-LBCL), originate in sites with limited immune surveillance. Owing to their rarity, the prognostic implications of the tumor microenvironment in IP-LBCLs remain unclear, warranting further investigation. This study evaluated 109 IP-LBCL cases (PCNS-LBCL, n=87; PT-LBCL, n=22; six cases of PVR-LBCL excluded) using multiplex immunohistochemistry on tissue microarrays, along with clinicopathological analysis. Immune cell infiltration, tumor major histocompatibility complex (MHC) class I, and programmed death ligand-1 (PD-L1) expression, and their associations with clinical outcomes, were evaluated. PT-LBCL demonstrated higher infiltration of all tumor-infiltrating T lymphocyte (TIL) subsets than PCNS-LBCL (all p<0.05). Elevated CD4⁺ and CD8⁺ T-cell levels correlated with prolonged progression-free survival (PFS) (both p<0.05). M1 macrophage infiltration was associated with improved PFS (p=0.005) and independently predicted a favorable prognosis (hazard ratio = 0.49, p=0.041). Loss of MHC class I expression was more frequent in PT-LBCL than in PCNS-LBCL (77.3% vs. 9.2%; p<0.001). TIL infiltration predicted improved PFS only when the tumor MHC class I was preserved. Moreover, programmed death protein-1 (PD-1)⁺ TILs and tumor PD-L1 expression were associated with prognosis in conjunction with various clinicopathological variables. These findings highlight the favorable prognostic role of TILs and M1 macrophages, and underscore the complex immune-tumor interactions in IP-LBCLs, despite their origin in immune-privileged sites.

#5

Whole-Eye Radiation for the Local Control of Choroidal Lymphoma in Primary Central Nervous System Lymphoma: A 14-Year Case Study.

Cureus2025 Jun

Involved-site radiation therapy is effective for curative and palliative treatments of cancers, including lymphoma. This case study describes the use of whole-eye radiation for primary intraocular lymphoma occurring during primary central nervous system lymphoma. The patient, a 68-year-old man, developed personality changes and apathy two weeks after cataract surgery combined with vitrectomy for vitreous opacity in the left eye. Magnetic resonance imaging revealed a mass lesion in the left frontal lobe, and biopsy by craniotomy confirmed diffuse large B-cell lymphoma. He underwent chemotherapy using rituximab combined with high-dose methotrexate and high-dose cytarabine in association with intrathecal methotrexate and cytarabine injections, leading to complete remission. At age 75, he noticed forgetfulness, and fluorodeoxyglucose positron emission tomography and magnetic resonance imaging revealed a relapse of lymphoma in the splenium of the corpus callosum. He underwent chemotherapy using rituximab combined with high-dose methotrexate, followed by monthly rituximab monotherapy for one year and then rituximab monotherapy every two months for one year. He maintained complete remission with no treatment until age 78, when he developed subretinal choroidal lesions in the left eye and underwent whole-eye radiation at 40 Gy. One year later, he developed subretinal choroidal lesions in the right eye and underwent whole-eye radiation at 40 Gy. At age 81, he had lower limb weakness with disorientation. Magnetic resonance imaging showed a relapse of lymphoma in the right frontal to temporal lobe. The brain lesions showed a marked response to four weeks of oral tirabrutinib as a salvage therapy, but the lesions regrew, and the patient died seven months later. Throughout the treatment, he maintained a visual acuity of 0.7 (decimal scale) in both eyes. In conclusion, whole-eye radiation should be considered as a treatment option for the local control of active intraocular lymphoma, especially choroidal lesions, for patients with primary central nervous system lymphoma with no active brain lesions and without systemic treatment.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 94

2026

Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.

Scientific reports
2025

Intraocular Lymphoma: A Review.

Journal of ophthalmic &amp; vision research
2026

Immune-Mediated Macular Edema After Intravitreal Methotrexate in Primary Vitreoretinal Lymphoma.

Ocular immunology and inflammation
2025

Clinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.

Cancer research and treatment
2025

Whole-Eye Radiation for the Local Control of Choroidal Lymphoma in Primary Central Nervous System Lymphoma: A 14-Year Case Study.

Cureus
2025

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B-Cell Lymphoma of Immune-Privileged Sites.

Hematological oncology
2025

Molecular diagnosis of vitreoretinal lymphoma.

Taiwan journal of ophthalmology
2025

Optimal utilization of paucicellular vitreous sample for diagnosis of primary vitreoretinal lymphoma.

Journal of the American Society of Cytopathology
2025

A Natural Course From Primary Intraocular Lymphoma to Brain Lymphoma in Four Years According to Patient's Choice.

Cureus
2025

In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.

Frontiers in immunology
2025

A case of primary intraocular B-cell lymphoma masquerading alongside varicella-zoster virus retinitis.

American journal of ophthalmology case reports
2025

A glaucoma drainage implant functioning as a sanctuary site for vitreoretinal lymphoma.

American journal of ophthalmology case reports
2025

Advances in primary large B-cell lymphoma of immune-privileged sites.

Frontiers in immunology
2024

Primary Cerebral Lymphoma With Isolated Vitreoretinal and Cerebral Recurrences Without Meningeosis: A Case Report.

Cureus
2025

Endoretinal biopsy outcomes in suspected vitreoretinal lymphoma after inconclusive vitreous cytology.

Journal francais d'ophtalmologie
2025

Mycophenolate Mofetil-Induced Lymphoproliferative Disorder in a Young Adult With Chronic Posterior Uveitis.

Journal of vitreoretinal diseases
2024

Vitreoretinal large B- cell lymphoma (VR- LBCL): Clinical and pathological features and treatment outcomes.

Pathology, research and practice
2024

Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.

BMC neurology
2025

Transient Bacillary Layer Detachment During the Disease Course of Primary Vitreoretinal Lymphoma.

Ocular immunology and inflammation
2024

Not everything is ischemic optic neuropathy.

Survey of ophthalmology
2024

Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas.

Scientific reports
2024

Diagnosis of primary vitreoretinal lymphoma masquerading infectious retinitis by retinal biopsy.

Journal of ophthalmic inflammation and infection
2024

Cell-Free DNA Extraction of Vitreous and Aqueous Humor Specimens for Diagnosis and Monitoring of Vitreoretinal Lymphoma.

Journal of visualized experiments : JoVE
2024

Molecular Analysis of Liquid Vitreous Biopsy Reveals Occult Lymphoma Following Cytology-Negative Biopsies of the Brain and Vitreous.

Ocular immunology and inflammation
2023

Primary Autologous Stem Cell Transplantation for Unilateral Primary Central Nervous System Lymphoma-Ophthalmic Variant (Primary Vitreoretinal Lymphoma).

Journal of vitreoretinal diseases
2023

[Molecular diagnostics for vitreoretinal lymphoma].

Pathologie (Heidelberg, Germany)
2023

Vitreoretinal lymphoma: a diagnostic challenge.

Archivos de la Sociedad Espanola de Oftalmologia
2025

A CASE OF EPSTEIN-BARR VIRUS-ASSOCIATED PRIMARY VITREORETINAL LYMPHOMA IN AN IMMUNOSUPPRESSED PATIENT.

Retinal cases &amp; brief reports
2023

Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study.

Cancers
2024

Cloudy Vitelliform Submaculopathy as an Early Sign of Primary Vitreoretinal Lymphoma.

Retina (Philadelphia, Pa.)
2024

PRIMARY VITREORETINAL LYMPHOMA MASQUERADING AS POSTOPERATIVE ENDOPHTHALMITIS IN A PREGNANT PATIENT WITH LONG-STANDING IDIOPATHIC PANUVEITIS.

Retinal cases &amp; brief reports
2024

VITREORETINAL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT IN A PATIENT WITH SARCOIDOSIS: A CASE REPORT.

Retinal cases &amp; brief reports
2023

Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma.

Neuropathology and applied neurobiology
2024

AN UNUSUAL CASE OF PRIMARY VITREORETINAL LYMPHOMA: A TRANSFORMED LYMPHOMA.

Retinal cases &amp; brief reports
2022

[Use of optical coherence tomography in diagnosis of retinal lymphomas].

Vestnik oftalmologii
2022

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.

Journal of hematology &amp; oncology
2022

[Lymphoma of the eye and its adnexa : Modern pathological diagnostics and systemic treatment].

Die Ophthalmologie
2022

Steroid-induced delayed diagnosis of primary vitreoretinal lymphoma with ghost brain tumor: A case report.

Medicine
2022

Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis.

Hematology (Amsterdam, Netherlands)
2022

A Rare Presentation of Primary Central Nervous System Lymphoma in an Immunocompetent Patient.

Cureus
2022

Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.

Cancers
2023

Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.

The British journal of ophthalmology
2022

Primary central nervous system lymphoma.

Blood
2021

Vitreoretinal lymphoma following primary testicular lymphoma: Report of two cases and review of the literature.

American journal of ophthalmology case reports
2021

Vitreoretinal lymphoma occurring after systemic chemotherapy for primary conjunctival diffuse large B cell lymphoma: A case report.

Medicine
2022

The molecular hallmarks of primary and secondary vitreoretinal lymphoma.

Blood advances
2021

How we treat primary central nervous system lymphoma.

ESMO open
2021

Rapid Resolution of Presumed Vitreoretinal Lymphoma With Systemic Ibrutinib Therapy.

Ophthalmic surgery, lasers &amp; imaging retina
2021

Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.

Ocular immunology and inflammation
2021

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.

Frontiers in oncology
2022

Rapid, Spontaneous Resolution of Prominent Subretinal Infiltrate in Vitreoretinal Lymphoma.

Journal of vitreoretinal diseases
2021

Clinical characteristics and treatment outcomes of diffuse large B-cell lymphoma involving the eye and ocular adnexa in East Asia.

Acta ophthalmologica
2020

Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.

Diagnostics (Basel, Switzerland)
2021

Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation.

Ophthalmology
2020

Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma.

Ophthalmic surgery, lasers &amp; imaging retina
2021

A diagnostic challenge of primary Central nervous system lymphoma: from the eyes to the brain.

The International journal of neuroscience
2020

Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.

BMC ophthalmology
2020

Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Blood advances
2020

Eye involvement in primary central nervous system lymphoma.

Survey of ophthalmology
2020

Gene expression profiling of primary vitreoretinal lymphoma.

Cancer science
2020

HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.

Retina (Philadelphia, Pa.)
2019

Clinical Features of Primary and Systemic Metastatic Intraocular Lymphomas in Spanish Patients.

Journal of ophthalmology
2020

Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation.

Survey of ophthalmology
2021

Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.

Ocular immunology and inflammation
2019

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

European journal of cancer (Oxford, England : 1990)
2020

Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis.

Ocular immunology and inflammation
2019

Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma.

JAMA ophthalmology
2019

Paraneoplastic Granulomatous Vitritis: Elaboration of 8 Cases.

Ophthalmology. Retina
2019

Cytological diagnosis of vitreoretinal lymphomas: A case series.

Cytopathology : official journal of the British Society for Clinical Cytology
2019

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Annals of oncology : official journal of the European Society for Medical Oncology
2019

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

American journal of hematology
2018

An unusual case report of primary vitreoretinal lymphoma.

BMC ophthalmology
2018

Primary Vitreoretinal Lymphoma Presenting as a Posterior Capsule Plaque.

Ophthalmic surgery, lasers &amp; imaging retina
2021

CYSTOID MACULAR EDEMA IN THE SETTING OF PRIMARY VITREORETINAL LYMPHOMA.

Retinal cases &amp; brief reports
2018

The diagnosis and treatment of primary vitreoretinal lymphoma: a review.

International journal of retina and vitreous
2018

Emerging diagnostic tests for vitreoretinal lymphoma: a review.

Clinical &amp; experimental ophthalmology
2018

Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.

Ocular immunology and inflammation
2017

[Malignant lymphomas of the eye].

Der Pathologe
2017

Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region.

JAMA ophthalmology
2017

[Primary central nervous system lymphoma: pathogenesis and histomorphology].

Magyar onkologia
2018

Two cases of primary vitreoretinal lymphoma: a diagnostic challenge : The supporting role of multimodal imaging in the diagnosis of primary vitreoretinal lymphoma.

International ophthalmology
2017

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Oncotarget
2016

Histopathologic Diagnosis of Atypical Primary Vitreoretinal Lymphoma following Enucleation.

Ocular oncology and pathology
2016

Primary Intraocular Diffuse Large B-cell Lymphoma: Diagnostic Difficulties in Deep Retinal Infiltrations with Vitritis.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2016

Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.

BMC ophthalmology
2016

Optical coherence tomography manifestations of primary vitreoretinal lymphoma.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2017

Clinical Features of Systemic Metastatic Retinal Lymphoma in Japanese Patients.

Ocular immunology and inflammation
2016

PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.

Retina (Philadelphia, Pa.)
2015

Advances in Primary Central Nervous System Lymphoma.

Current oncology reports
2015

[Intraocular lymphoma associated with primary malignant lymphoma of the central nervous system: Seven-year experience of a tertiary center].

Journal francais d'ophtalmologie
2015

Primary vitreoretinal lymphoma.

Indian journal of ophthalmology
2015

High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.

Blood
2015

Correlation between measurement of IL-10 and IL-6 in paired aqueous humour and vitreous fluid in primary vitreoretinal lymphoma.

Acta ophthalmologica
2015

[Diagnostics and treatment of primary vitreoretinal lymphoma].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Primary vitreoretinal large B-cell lymphoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Primary vitreoretinal large B-cell lymphoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.
    Scientific reports· 2026· PMID 41690970mais citado
  2. Immune-Mediated Macular Edema After Intravitreal Methotrexate in Primary Vitreoretinal Lymphoma.
    Ocular immunology and inflammation· 2026· PMID 41290229mais citado
  3. Intraocular Lymphoma: A Review.
    Journal of ophthalmic &amp; vision research· 2025· PMID 41403850mais citado
  4. Clinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.
    Cancer research and treatment· 2025· PMID 40808531mais citado
  5. Whole-Eye Radiation for the Local Control of Choroidal Lymphoma in Primary Central Nervous System Lymphoma: A 14-Year Case Study.
    Cureus· 2025· PMID 40642723mais citado
  6. Mast cell mediators in hereditary angioedema.
    Orphanet J Rare Dis· 2026· PMID 41832580recente
  7. Prenatal Molecular Diagnosis of COL2A1-Associated Stickler Syndrome: Genotype-Phenotype Correlation in a Resource-Limited Healthcare Setting.
    Int J Mol Sci· 2026· PMID 41828453recente
  8. Platelet gene signatures detecting pulmonary artery stenosis in patients with pulmonary hypertension.
    Orphanet J Rare Dis· 2026· PMID 41827036recente
  9. The global impact of imiglucerase therapy in children with Gaucher disease types 1 and 3: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
    Orphanet J Rare Dis· 2026· PMID 41821052recente
  10. Monogenic lupus with SLC7A7 mutations: a retrospective study from a Chinese center.
    Orphanet J Rare Dis· 2026· PMID 41821046recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:695631(Orphanet)
  2. MONDO:0979292(MONDO)
  3. Busca completa no PubMed(PubMed)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Primary vitreoretinal large B-cell lymphoma
Compêndio · Raras BR

Primary vitreoretinal large B-cell lymphoma

ORPHA:695631 · MONDO:0979292
MedGen
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades